Ulan Bator, Sep 20. -The specialist from the Center for Genetic Engineering and Biotechnology of Cuba, Yanisbel Ortiz began today in Mongolia the training of this Asian country in the use of the new drug Heberprot P.
This unique Cuban drug, prescribed for the therapy of diabetic foot ulcer and based on human growth factor, reduces the risk of amputation due to this condition.
Ortiz, who is a first-degree specialist in Angiology and Vascular Surgery and a member of the Angiology and Vascular Surgery Society of Cuba, began his counseling at the Songdo hospital in this capital.
She was also invited to the National Symposium on Diabetes that is held today and tomorrow, in which she will give a masterly conference on the use of this drug and on the National Diabetes Care Program implemented in Cuba, highlighted the ambassador in Mongolia, Raúl Delgado in his Facebook account.
The Heberprot-P, which has benefited around 300,000 patients worldwide, is registered in more than 20 countries, including Russia, Kuwait, Ukraine, Argentina, Turkey, Vietnam and Colombia.
In Cuba, more than 77,300 affected by diabetic foot ulcer have been treated since 2007, which has led to the reduction of amputation by 70 percent. (Taken from Prensa Latina)